A new strategy that combines two types of PET scans can guide personalized radiotherapy for head and neck cancers, according ...

The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...

A recent retrospective study identifies key factors contributing to high failure rates of clinical trials evaluating treatments for head and neck squamous cell carcinoma.

The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.

'Touch' encourages people to check for lumps on the neck, lips, or in their mouth. The 'open wide' part of the campaign aims ...

The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...

A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients ...

For the last 20 years, the standard-of-care adjuvant treatment for resected pathologically defined high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) has been ...

The Head and Neck Cancer Timely Presentation Campaign launches in Birkenhead, urging early detection with self-checks for men at high risk ...

A Phase III clinical trial including patients at the University of Oklahoma found that proton therapy improved survival and ...

Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most common reasons are sponsor decisions related to safety or effectiveness and ...